PPARG and urinary bladder cancer: The activation of PPARγ by mutations may, therefore, result in PPARγ-dependence not only in bladder cancer, but also in other types of cancer, reinforcing the importance of developing new pharmacological approaches targeting the ligand-independent activity of PPARγ in tumors.